EPIX Pharmaceuticals to Present at the Eighth Annual Structure-Based Drug Design ConferenceLEXINGTON, Mass.--(BUSINESS WIRE)--Jun 19, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that Sharon Shacham, Ph.D., vice president of drug development at EPIX, is scheduled to present at the Eighth Annual Structure-Based Drug Design Conference at the World Trade Center in Boston on Friday, June 27, 2008 at 11:00 a.m. (ET). Dr. Shacham's presentation will take place during a session that focuses on Structure-Based Modeling of GPCRs and the presentation will feature EPIX's unique approach to drug discovery including their proprietary PREDICT(TM) technology.
The conference is sponsored by Cambridge Healthtech Institute and is intended to provide cutting-edge advances in various areas of research of drug design and discovery. The conference will bring together an international delegation of chemists, computational chemists, applications scientists, medicinal chemists and research technologists.
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma. For more information, please visit the company's website at www.epixpharma.com.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Kim C. Drapkin, 781-761-7602
Chief Financial Officer
Kelly Hennessy, 617-227-0552
Posted: June 2008